The rise of copyright’s drug initially fueled significant progress in the drug sector, generating a image of guaranteed gains. However, investing in companies solely reliant on top-selling drugs like the erectile dysfunction pill presents significant challenges. Exclusive rights expiry has led off-brand challenge, reducing sales share and potent… Read More

The recent surge in investments into boutique pharmaceutical companies, particularly those focusing on novel therapies and challenging drug development programs, has fueled what some are calling "High Investor Pharma." While the possibility for game-changing treatments and impressive returns is certain, the associated risks are also considerable… Read More